{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:40:47Z","timestamp":1793400047833,"version":"4.5.0"},"reference-count":31,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"abstract":"\n Importance<\/jats:title>\n Transcatheter aortic valve implant (TAVI) is increasingly being performed in younger and healthier patients with severe aortic valve stenosis. Antithrombotic therapy after TAVI is a key element of optimizing valve durability and clinical outcomes.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the safety and efficacy of a factor Xa inhibitor non\u2013vitamin K antagonist oral anticoagulant (NOAC) monotherapy strategy vs an acetylsalicylic acid (ASA) monotherapy strategy after TAVI.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Between December 2021 and June 2025, 360 participants between the ages of 65 and 80 years undergoing TAVI for severe aortic valve stenosis were enrolled in this prospective, randomized, open-label, blinded end point trial conducted at 3 Norwegian centers managing the majority of TAVI procedures nationally. The last patient completed follow-up on May 19, 2026.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n A total of 360 participants were randomly assigned (1:1) to receive 12 months of monotherapy with either NOAC (intervention) or ASA (control).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n A predefined co\u2013primary end point strategy was chosen to address both efficacy and safety. The primary efficacy end point was TAVI valve leaflet thrombosis defined as the presence of hypoattenuated leaflet thickening (HALT) on blinded core laboratory 4-dimensional cardiac computed tomographic (CT) scan at 12 months. The primary safety end point was a composite of adjudicated Valve Academic Research Consortium 3 (VARC-3) bleeding events, thromboembolic events, and all-cause death at 12 months.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of the 360 participants randomized (mean age, 74.5 years [SD, 3.7]; 134 females [37%]), 336 completed the trial (168 in each group). The primary efficacy end point occurred in 27 participants (16.2%) allocated to the NOAC group and in 48 participants (28.6%) allocated to the ASA group (risk ratio, 0.55; 95% CI, 0.37 to 0.82,\n P<\/jats:italic>\n \u2009=\u2009.004). The primary safety end point occurred in 13 participants (7.5%) in the NOAC group and in 19 participants (10.6%) in the ASA group (risk difference, \u22123.3%; 95% CI, \u22129.5% to 2.8%;\n P<\/jats:italic>\n for noninferiority &amp;lt;.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n A strategy of NOAC monotherapy after TAVI reduced the incidence of HALT and was noninferior for bleeding, thromboembolic events, or death compared with acetylsalicylic acid monotherapy. These findings suggest that anticoagulation therapy can be beneficial after TAVI in selected patients.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT05035277<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2026.17036","type":"journal-article","created":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T10:30:15Z","timestamp":1788085815000},"source":"Crossref","is-referenced-by-count":3,"title":["Anticoagulation Monotherapy vs Antiplatelet Monotherapy After Transcatheter Aortic Valve Implant"],"prefix":"10.1001","author":[{"given":"Christopher S.","family":"Dodgson","sequence":"first","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway"},{"name":"Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Herstad","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Haukeland University Hospital, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie F.","family":"Kl\u00f8ve","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Flygel","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Haukeland University Hospital, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Akhavi","sequence":"additional","affiliation":[{"name":"Intervention Centre, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sverre","family":"H\u00f8ie","sequence":"additional","affiliation":[{"name":"Department of Cardiology, S\u00f8rlandet Hospital Arendal, Arendal, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Otto","family":"Beitnes","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian H.","family":"Eek","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaspar","family":"Broch","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Cunen","sequence":"additional","affiliation":[{"name":"Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Gullestad","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Aaberge","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketil","family":"Lunde","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn","family":"Bendz","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway"},{"name":"Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8yvind H.","family":"Lie","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,8,30]]},"reference":[{"issue":"14","key":"joi260097r1","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1016\/j.jcin.2024.04.047","article-title":"A guide to transcatheter aortic valve design and systematic planning for a Redo-TAV (TAV-in-TAV) procedure.","volume":"17","author":"Bapat","year":"2024","journal-title":"JACC Cardiovasc Interv"},{"issue":"44","key":"joi260097r2","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.1093\/eurheartj\/ehaf194","article-title":"2025 ESC\/EACTS guidelines for the management of valvular heart disease.","volume":"46","author":"Praz","year":"2025","journal-title":"Eur Heart J"},{"issue":"1","key":"joi260097r3","doi-asserted-by":"publisher","first-page":"73.e39","DOI":"10.1016\/j.crad.2020.08.015","article-title":"Bioprosthetic valve thrombosis and degeneration following transcatheter aortic valve implantation (TAVI).","volume":"76","author":"Mirsadraee","year":"2021","journal-title":"Clin Radiol"},{"issue":"1","key":"joi260097r4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jcmg.2018.06.028","article-title":"Transcatheter aortic heart valves: histological analysis providing insight to leaflet thickening and structural valve degeneration.","volume":"12","author":"Sellers","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"joi260097r5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.124.014523","article-title":"Pathology of self-expanding transcatheter aortic bioprostheses and hypoattenuated leaflet thickening.","volume":"18","author":"Sato","year":"2025","journal-title":"Circ Cardiovasc Interv"},{"issue":"21","key":"joi260097r6","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1056\/NEJMoa1509233","article-title":"Possible subclinical leaflet thrombosis in bioprosthetic aortic valves.","volume":"373","author":"Makkar","year":"2015","journal-title":"N Engl J Med"},{"issue":"24","key":"joi260097r7","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1016\/j.jacc.2020.04.043","article-title":"Subclinical leaflet thrombosis in transcatheter and surgical bioprosthetic valves: PARTNER 3 cardiac computed tomography substudy.","volume":"75","author":"Makkar","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"joi260097r8","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1016\/j.jacc.2020.03.022","article-title":"Bioprosthetic aortic valve leaflet thickening in the evolut low risk sub-study.","volume":"75","author":"Blanke","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"joi260097r9","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1016\/j.jcin.2021.09.019","article-title":"Subclinical leaflet thrombosis after transcatheter aortic valve replacement: a meta-analysis.","volume":"14","author":"Bogyi","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"issue":"10087","key":"joi260097r10","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1016\/S0140-6736(17)30757-2","article-title":"Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study.","volume":"389","author":"Chakravarty","year":"2017","journal-title":"Lancet"},{"issue":"28","key":"joi260097r11","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1093\/eurheartj\/ehx369","article-title":"Natural history of subclinical leaflet thrombosis affecting motion in bioprosthetic aortic valves.","volume":"38","author":"Sondergaard","year":"2017","journal-title":"Eur Heart J"},{"issue":"11","key":"joi260097r12","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.jcin.2022.04.018","article-title":"Long-term follow-up of hypoattenuated leaflet thickening after transcatheter aortic valve replacement.","volume":"15","author":"Hein","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"issue":"3","key":"joi260097r13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.121.011480","article-title":"Clinical impact of hypoattenuating leaflet thickening after transcatheter aortic valve replacement.","volume":"15","author":"Garcia","year":"2022","journal-title":"Circ Cardiovasc Interv"},{"issue":"2","key":"joi260097r14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1911426","article-title":"Reduced leaflet motion after transcatheter aortic-valve replacement.","volume":"382","author":"De Backer","year":"2020","journal-title":"N Engl J Med"},{"issue":"18","key":"joi260097r15","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1016\/j.jcin.2022.07.014","article-title":"Apixaban and valve thrombosis after transcatheter aortic valve replacement: the ATLANTIS-4D-CT randomized clinical trial substudy.","volume":"15","author":"Montalescot","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"issue":"2","key":"joi260097r16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa1911425","article-title":"A controlled trial of rivaroxaban after transcatheter aortic-valve replacement.","volume":"382","author":"Dangas","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"joi260097r17","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1161\/CIRCULATIONAHA.122.059512","article-title":"Edoxaban versus dual antiplatelet therapy for leaflet thrombosis and cerebral thromboembolism after TAVR: the ADAPT-TAVR randomized clinical trial.","volume":"146","author":"Park","year":"2022","journal-title":"Circulation"},{"issue":"29","key":"joi260097r18","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1093\/eurheartj\/ehac242","article-title":"Apixaban vs standard of care after transcatheter aortic valve implantation: the ATLANTIS trial.","volume":"43","author":"Collet","year":"2022","journal-title":"Eur Heart J"},{"issue":"18","key":"joi260097r19","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa1915152","article-title":"Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation.","volume":"382","author":"Nijenhuis","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"joi260097r20","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1016\/j.jacc.2020.11.018","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines.","volume":"77","author":"Otto","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"joi260097r21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ahj.2023.08.010","article-title":"An investigator-sponsored pragmatic randomized controlled trial of anticoagulation vs acetylsalicylic acid after transcatheter aortic valve implantation: rationale and design of ACASA-TAVI.","volume":"265","author":"Dodgson","year":"2023","journal-title":"Am Heart J"},{"issue":"1","key":"joi260097r22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jama.2024.21972","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human participants.","volume":"333","author":"World Medical Association","year":"2025","journal-title":"JAMA"},{"issue":"19","key":"joi260097r23","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1093\/eurheartj\/ehaa799","article-title":"Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research.","volume":"42","author":"G\u00e9n\u00e9reux","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"joi260097r24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.120.009983","article-title":"Randomized trial of aspirin versus warfarin after transcatheter aortic valve replacement in low-risk patients.","volume":"14","author":"Rogers","year":"2021","journal-title":"Circ Cardiovasc Interv"},{"issue":"15","key":"joi260097r25","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1056\/NEJMoa2017815","article-title":"Aspirin with or without clopidogrel after transcatheter aortic-valve implantation.","volume":"383","author":"Brouwer","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"joi260097r27","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation.","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"joi260097r28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa2310234","article-title":"Apixaban for stroke prevention in subclinical atrial fibrillation.","volume":"390","author":"Healey","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"joi260097r29","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/jama.2023.27188","article-title":"Apixaban to prevent recurrence after cryptogenic stroke in patients with atrial cardiopathy: the ARCADIA randomized clinical trial.","volume":"331","author":"Kamel","year":"2024","journal-title":"JAMA"},{"issue":"3","key":"joi260097r30","doi-asserted-by":"publisher","first-page":"360","DOI":"10.7326\/ANNALS-24-02132","article-title":"Bleeding risks with non\u2013vitamin K oral anticoagulants versus single antiplatelet therapy: a systematic review and meta-analysis of randomized trials.","volume":"178","author":"Wang","year":"2025","journal-title":"Ann Intern Med"},{"issue":"11","key":"joi260097r31","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1056\/NEJMoa2510703","article-title":"Bleeding risk with apixaban vs. rivaroxaban in acute venous thromboembolism.","volume":"394","author":"Castellucci","year":"2026","journal-title":"N Engl J Med"},{"key":"joi260097r26","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials: E9(R1). November 20, 2019. Accessed June 7, 2026, https:\/\/database.ich.org\/sites\/default\/files\/E9-R1_Step4_Guideline_2019_1203.pdf"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2853401\/jama_dodgson_2026_oi_260097_1787333130.47014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T10:30:16Z","timestamp":1788085816000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2853401"}},"subtitle":["The ACASA-TAVI Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,8,30]]},"references-count":31,"URL":"https:\/\/doi.org\/10.1001\/jama.2026.17036","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,30]]}}}